Compare Peptides

Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.

Popular comparisons

Thymosin Beta-4

Tβ4, Full-length TB4

Unregulated
Healing & Recovery

Thymosin Alpha-1

Tα1, Zadaxin

Category 1
Immune Support
Overview

The full-length 43-amino acid peptide from which TB-500 is derived. Thymosin Beta-4 is the most abundant member of the beta-thymosin family and plays a central role in tissue repair, cell migration, and anti-inflammatory signaling.

A thymic peptide that plays a central role in immune system regulation. Approved as a drug in over 35 countries (though not in the US) for hepatitis B and C treatment and as an immune booster.

Mechanism of Action

Sequesters G-actin monomers, regulating actin polymerization critical for cell motility and wound healing. Promotes angiogenesis, reduces inflammation via NF-κB modulation, and supports stem cell differentiation. TB-500 is a synthetic fragment of the active region.

Enhances T-cell function, promotes dendritic cell maturation, and modulates cytokine production. Acts as an immune system regulator rather than a simple stimulant, helping to balance immune responses.

Common Uses
  • Tissue repair and wound healing
  • Cardiac tissue protection
  • Corneal healing
  • Anti-inflammatory support
  • Hair regrowth
  • Immune system support
  • Chronic infection management
  • Cancer adjunct therapy (in some countries)
  • Post-illness recovery
  • Autoimmune condition management
Known Risks
  • Limited human clinical data for injectable form
  • Theoretical oncogenesis concerns (promotes cell migration)
  • More expensive than TB-500 fragment
  • Injection site reactions
  • Generally well-tolerated in clinical use
  • Injection site reactions
  • Rare allergic reactions
  • May interact with immunosuppressive drugs
Regulatory Status
Unregulated

No FDA regulatory category for the full-length peptide. TB-500 (the fragment) is pending PCAC review. The full-length Thymosin Beta-4 is available only as a research chemical.

Category 1

Reclassified to Category 1 in February 2026 as part of the HHS announcement restoring compounding access. Not affected by the April 15, 2026 Category 2 removal action. Approved as Zadaxin in 35+ countries but not FDA-approved in the US. Available through licensed 503A compounding pharmacies with a physician prescription.

This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.